Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

Purpose As part of the American Association of Physicists in Medicine Working Group on
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …

Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …

Background Combination nivolumab plus ipilimumab was efficacious in patients with
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …

Background Patients with HER2-positive metastatic breast cancer have a high risk of
developing brain metastases. Efficacious treatment options are scarce. We investigated the …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor
receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported …

Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and
melanoma, is associated with poor survival outcomes and poses distinct clinical challenges …

Background Alterations involving the RET kinase are implicated in the pathogenesis of lung,
thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with …